GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » E10

Sarepta Therapeutics (Sarepta Therapeutics) E10 : $-6.44 (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Sarepta Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.370. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-6.44 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -10.70% per year. During the past 5 years, the average E10 Growth Rate was -13.80% per year. During the past 10 years, the average E10 Growth Rate was -9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Sarepta Therapeutics was 11.80% per year. The lowest was -18.60% per year. And the median was -3.00% per year.

As of today (2024-05-16), Sarepta Therapeutics's current stock price is $132.74. Sarepta Therapeutics's E10 for the quarter that ended in Mar. 2024 was $-6.44. Sarepta Therapeutics's Shiller PE Ratio of today is .


Sarepta Therapeutics E10 Historical Data

The historical data trend for Sarepta Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics E10 Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.29 -4.84 -5.70 -6.21 -6.57

Sarepta Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.73 -6.76 -6.70 -6.57 -6.44

Competitive Comparison of Sarepta Therapeutics's E10

For the Biotechnology subindustry, Sarepta Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Shiller PE Ratio falls into.



Sarepta Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sarepta Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.37/131.7762*131.7762
=0.370

Current CPI (Mar. 2024) = 131.7762.

Sarepta Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -0.850 100.560 -1.114
201409 -0.710 100.428 -0.932
201412 -1.080 99.070 -1.437
201503 -1.490 99.621 -1.971
201506 -1.010 100.684 -1.322
201509 -1.250 100.392 -1.641
201512 -1.440 99.792 -1.902
201603 -1.310 100.470 -1.718
201606 -1.350 101.688 -1.749
201609 -1.180 101.861 -1.527
201612 -1.620 101.863 -2.096
201703 1.500 102.862 1.922
201706 -1.150 103.349 -1.466
201709 -0.780 104.136 -0.987
201712 -0.370 104.011 -0.469
201803 -0.550 105.290 -0.688
201806 -1.670 106.317 -2.070
201809 -1.150 106.507 -1.423
201812 -2.052 105.998 -2.551
201903 -1.070 107.251 -1.315
201906 -3.740 108.070 -4.560
201909 -1.700 108.329 -2.068
201912 -3.170 108.420 -3.853
202003 -0.230 108.902 -0.278
202006 -1.930 108.767 -2.338
202009 -2.500 109.815 -3.000
202012 -2.410 109.897 -2.890
202103 -2.100 111.754 -2.476
202106 -1.020 114.631 -1.173
202109 -0.600 115.734 -0.683
202112 -1.430 117.630 -1.602
202203 -1.200 121.301 -1.304
202206 -2.650 125.017 -2.793
202209 -2.940 125.227 -3.094
202212 -1.240 125.222 -1.305
202303 -5.860 127.348 -6.064
202306 -0.270 128.729 -0.276
202309 -0.460 129.860 -0.467
202312 0.760 129.419 0.774
202403 0.370 131.776 0.370

Add all the adjusted EPS together and divide 10 will get our e10.


Sarepta Therapeutics  (NAS:SRPT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Sarepta Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics (Sarepta Therapeutics) Business Description

Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Executives
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram director, officer: President & CEO 2525 DUPONT DR, IRVINE CA 92612
Michael Andrew Chambers director 215 FIRST STREET, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf director OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Bilal Arif officer: Chief Tech Ops Officer 215 FIRST STREET, CAMBRIDGE MA 02129
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Kathryn Jean Boor director 3736 S. MAIN STREET, MARION NY 14505
Louise Rodino-klapac officer: Chief Scientific Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Ryan Edward Brown officer: SVP, General Counsel 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Ian Michael Estepan officer: Chief Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Joseph Bratica officer: Principal Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton officer: SVP, General Counsel VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme officer: Senior Vice President, CFO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901